Advertisement

Related Videos

Welcome and Introduction to Vi3C

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Deborah Collyar: What's In It for Patients?

Varsha Gandhi, PhD, on Ibrutinib

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement




Nov
08
Today In Oncology
Long-Term Survivors of Hodgkin Lymphoma May Face Elevated Health Risks, Study Finds
OptiTROP-Lung06 A Potential Alternative to Chemotherapy in Advanced PD-L1–Negative NSCLC?
Ponatinib/Blinatumomab Improves Event-Free Survival in Ph-Positive ALL
American Lung Association and Prevent Cancer Foundation Host Virtual QIW Workshop: Advancing Routine Clinical Use of Health Information From Chest CT Screening for Public Health
Izalontamab Brengitecan Improves Progression-Free Survival in EGFR-Mutated Advanced Nonsquamous NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo